Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 18/20 | 0.82 |
| ▸ | FLT3 | P36888 | 11/20 | 0.80 |
| ▸ | SRC | P12931 | 10/20 | 0.80 |
| ▸ | KIT | P10721 | 9/20 | 0.80 |
| ▸ | AURKA | O14965 | 3/20 | 0.80 |
| ▸ | TTK | P33981 | 3/20 | 0.80 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.80 |
| ▸ | INCENP | Q9NQS7 | 3/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10062890 | 0.90 | ITK (1.00) | ITKFLT3SRCKITAURKA | |
| SCHEMBL10063203 | 0.89 | ITK (0.83) | ITKFLT3SRCKITAURKA | |
| SCHEMBL10062900 | 0.89 | ITK (1.00) | ITKFLT3SRCKITAURKA | |
| SCHEMBL10062888 | 0.89 | ITK (1.00) | ITKFLT3SRCKITAURKA | |
| SCHEMBL10062893 | 0.84 | ITK (0.84) | ITKFLT3SRCKITAURKA | |
| SCHEMBL10062892 | 0.84 | ITK (0.84) | ITKFLT3SRCKITAURKA | |
| SCHEMBL10062894 | 0.84 | ITK (0.84) | ITKFLT3SRCKITAURKA | |
| SCHEMBL10062891 | 0.84 | TTK (1.00) | ITKFLT3SRCKITAURKA | |
| SCHEMBL10062915 | 0.83 | ITK (0.85) | ITKFLT3SRCKITAURKA | |
| SCHEMBL725039 | 0.78 | MAPT (0.57) | ITKFLT3SRCKITAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831168-B1 | PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES. | VERTEX PHARMA (US) | 2014-07-02 | — | — | EP | disclosed |
| US-20130184259-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184259-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| US-8338597-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338597-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120190699-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190699-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-26 | — | — | US | disclosed |
| US-8101770-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101770-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190699-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | MAP3K20, MAP3K6, MAP3K5 | ITK 393/4885FLT3 412/4885SRC 339/4885 |
| US-20130184259-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | MAP3K20, MAP3K6, MAP3K5 | ITK 393/4885FLT3 412/4885SRC 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.